Daniel Niewodowski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Daniel Niewodowski has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Bradley J. Gardiner
Department of Infectious Diseases, Alfred Health and School of Translational Medicine, Monash University, Melbourne, VIC, Australia
1 shared publication - David P. Nadebaum
Department of Nuclear Medicine & PET, Alfred Health, Melbourne, Australia
1 shared publication - Hayley Barnes
Faculty of Medicine, Nursing, and Health Sciences, Monash University Monash Centre for Occupational and Environmental Health, School of Public Health and Preventive Medicine Melbourne, Victoria
1 shared publication - Jun K Khoo
Department of Respiratory Medicine, Alfred Health, Melbourne, Australia
1 shared publication - Jyotika Devi Prasad
Respiratory and Lung Transplant, Alfred Hospital, Melbourne, Australia
1 shared publication - Martin H. Cherk
Department of Nuclear Medicine & PET, Alfred Health, Melbourne, Australia
1 shared publication
Latest Publications
- Open Access
- 4 June 2026
- Published by Korean Society of Occupational & Environmental Medicine in Annals of Occupational and Environmental Medicine
- Vol. 38, e16
Evaluating the efficacy of prednisolone for silicosis with progressive massive fibrosis in Australia: an observational pilot study
Background: There has been a resurgence of silicosis, particularly related to artificial stone. There are currently no treatments for silicosis beyond lung transplantation for end-stage disease. This study aimed to evaluate the efficacy of prednisolone in people with artificial stone-associated silicosis–progressive massive fibrosis (PMF).Methods: This was a pilot prospective observational clinical trial, assessing 3 months of prednisolone in adults with artificial stone–associated silicosis with PMF. Outcomes were assessed at 3 and 12 months.Results: Seven participants completed the study. Baseline positron emission tomography (PET) scans demonstrated increased fluorine-18 fluorodeoxyglucose (18F-FDG) uptake in areas of PMF in all participants. All participants had a significant reduction in maximum standardized uptake value (SUVmax) following prednisolone at 3 months (pre-treatment mean SUVmax 6.7 [standard deviation (SD): 2.6], post-treatment mean SUVmax 4.2 [SD: 1.0], p = 0.012). There was also a non-significant reduction in the % of total lung parenchyma with SUV >1 (49.7% [SD: 36.4] to 45.8% [SD: 28.4], p = 0.527) and a significant reduction in SUV >2.5 (7.0% [SD: 6.3] to 2.4% [SD: 2.2], p = 0.038). There was a non-significant reduction in computed tomography ICOERD well-defined opacity profusion scores and large opacities. There was no significant difference in lung function or St. George's Respiratory Questionnaire. There were no serious adverse events.Conclusions: There are high levels of inflammation in silicosis-PMF as evidenced by 18F-FDG PET. Short-term prednisolone reduced 18F-FDG PET activity. This suggests a possible therapeutic pathway for people with silicosis-associated PMF in a population with no current treatments. Further research is required to determine the most appropriate immunosuppressive strategy and further assess longer-term outcomes.
- 4 June 2026
- Published by Korean Society of Occupational & Environmental Medicine in Annals of Occupational and Environmental Medicine
- Vol. 38, e16
Open AccessEvaluating the efficacy of prednisolone for silicosis with progressive massive fibrosis in Australia: an observational pilot study
Background: There has been a resurgence of silicosis, particularly related to artificial stone. There are currently no treatments for silicosis beyond lung transplantation for end-stage disease. This study aimed to evaluate the efficacy of prednisolone in people with artificial stone-associated silicosis–progressive massive fibrosis (PMF).Methods: This was a pilot prospective observational clinical trial, assessing 3 months of prednisolone in adults with artificial stone–associated silicosis with PMF. Outcomes were assessed at 3 and 12 months.Results: Seven participants completed the study. Baseline positron emission tomography (PET) scans demonstrated increased fluorine-18 fluorodeoxyglucose (18F-FDG) uptake in areas of PMF in all participants. All participants had a significant reduction in maximum standardized uptake value (SUVmax) following prednisolone at 3 months (pre-treatment mean SUVmax 6.7 [standard deviation (SD): 2.6], post-treatment mean SUVmax 4.2 [SD: 1.0], p = 0.012). There was also a non-significant reduction in the % of total lung parenchyma with SUV >1 (49.7% [SD: 36.4] to 45.8% [SD: 28.4], p = 0.527) and a significant reduction in SUV >2.5 (7.0% [SD: 6.3] to 2.4% [SD: 2.2], p = 0.038). There was a non-significant reduction in computed tomography ICOERD well-defined opacity profusion scores and large opacities. There was no significant difference in lung function or St. George's Respiratory Questionnaire. There were no serious adverse events.Conclusions: There are high levels of inflammation in silicosis-PMF as evidenced by 18F-FDG PET. Short-term prednisolone reduced 18F-FDG PET activity. This suggests a possible therapeutic pathway for people with silicosis-associated PMF in a population with no current treatments. Further research is required to determine the most appropriate immunosuppressive strategy and further assess longer-term outcomes.